A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Trial

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.

开始日期2025-09-01

申办/合作机构

Eli Lilly & Co.

CTR20252895

/ Recruiting临床3期

在合并肥胖或超重的2型糖尿病参与者中评价orforglipron片剂每日一次给药相比安慰剂的有效性和安全性研究

研究GZP2 的目的是在合并超重或肥胖的T2D参与者接受 40 周治疗后比较 Orforglipron 与安慰剂对血糖控制的影响；此外，本研究还计划评估第 40 周直至 72 周治疗期间的体重减轻情况。

开始日期2025-08-07

申办/合作机构

礼来苏州制药有限公司

[+2]

CTR20252894

/ Recruiting临床3期

在合并和不合并2型糖尿病的肥胖或超重参与者中评价orforglipron片剂每日一次给药相比安慰剂的有效性和安全性研究

本主方案将支持两项独立研究（J2A-MC-GZP1和J2A-MC-GZP2），研究目的是在肥胖或伴至少 1 种其他体重相关合并症的超重参与者接受 40 周直至 72 周治疗后比较 Orforglipron 相比安慰剂对体重减轻的影响。

开始日期2025-08-07

申办/合作机构

礼来苏州制药有限公司

[+2]

100 项与奥格列龙相关的临床结果

登录后查看更多信息

100 项与奥格列龙相关的转化医学

登录后查看更多信息

100 项与奥格列龙相关的专利（医药）

登录后查看更多信息

项与奥格列龙相关的文献（医药）

2025-09-18·NEW ENGLAND JOURNAL OF MEDICINE

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

Article

作者: Eyde, Sarah ; Denning, Max ; Fernández Landó, Laura ; Rosenstock, Julio ; Ludwig, Lisa ; Nevarez Ruiz, Luis ; Chen, Yanyun ; Cox, David ; Liu, Rong ; Li, Jianghao ; Hsia, Stanley ; Wu, Wen-Shuo

BACKGROUND:

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and safety of orforglipron are needed.

METHODS:

In this phase 3, double-blind, placebo-controlled trial, we randomly assigned participants in a 1:1:1:1 ratio to receive orforglipron at one of three doses (3 mg, 12 mg, or 36 mg) or placebo once daily for 40 weeks. Participants had type 2 diabetes treated only with diet and exercise, a glycated hemoglobin level of at least 7.0% but no more than 9.5%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 23.0. The primary end point was the change from baseline to week 40 in the glycated hemoglobin level. A key secondary end point was the percent change in body weight from baseline to week 40.

RESULTS:

A total of 559 participants underwent randomization. The mean glycated hemoglobin level at baseline was 8.0%. At week 40, the estimated mean change from baseline in the glycated hemoglobin level was -1.24 percentage points with the 3-mg dose, -1.47 percentage points with the 12-mg dose, -1.48 percentage points with the 36-mg dose, and -0.41 percentage points with placebo. All three doses of orforglipron were superior to placebo with respect to the primary end point; the estimated mean difference from placebo was -0.83 percentage points (95% confidence interval [CI], -1.10 to -0.56) with the 3-mg dose, -1.06 percentage points (95% CI, -1.33 to -0.79) with the 12-mg dose, and -1.07 percentage points (95% CI, -1.33 to -0.81) with the 36-mg dose (P<0.001 for all comparisons). The mean glycated hemoglobin level at week 40 was 6.5 to 6.7% with orforglipron. The percent change in body weight from baseline to week 40 was -4.5% with the 3-mg dose, -5.8% with the 12-mg dose, -7.6% with the 36-mg dose, and -1.7% with placebo. The most common adverse events were mild-to-moderate gastrointestinal events, most of which occurred during dose escalation. No episodes of severe hypoglycemia were reported. Permanent discontinuation of orforglipron or placebo due to adverse events occurred in 4.4 to 7.8% of participants receiving orforglipron and 1.4% of participants receiving placebo.

CONCLUSIONS:

In adults with early type 2 diabetes, orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks. (Supported by Eli Lilly; ACHIEVE-1 ClinicalTrials.gov number, NCT05971940.).

2025-08-14·DIABETES OBESITY & METABOLISM

Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

Article

作者: Banerjee, Hiya ; Kazda, Christof ; Robins, Deborah A ; Rosenstock, Julio ; Lin, Yanzhu ; Konig, Manige ; Eyde, Sarah ; Wilson, Jonathan M ; Mather, Kieren J ; Duffin, Kevin L

AIMS:

These participant-level exploratory analyses evaluated the effects of orforglipron, a once-daily, orally administered non-peptide glucagon-like peptide-1 receptor agonist, versus dulaglutide and placebo, on β-cell function and insulin sensitivity biomarkers.

MATERIALS AND METHODS:

Participants (N = 378) in this 26-week phase 2 study with inadequately controlled type 2 diabetes (T2D) were randomly assigned to orforglipron (3, 12, 24, 36, or 45 mg), dulaglutide (1.5 mg), or placebo. Treatment effects on β-cell function and insulin sensitivity markers were assessed, including homeostatic model assessment indices of β-cell function and insulin resistance (HOMA-B and HOMA-IR, respectively); fasting C-peptide, insulin, serum glucose, and glucagon; adiponectin; insulin-like growth factor binding protein 2; proinsulin; and the proinsulin/insulin ratio.

RESULTS:

Orforglipron doses of 12 mg and higher were associated with improved β-cell function and insulin sensitivity. HOMA-B increased up to 123% (C-peptide) and 132% (insulin) with orforglipron doses of 12 mg and higher from baseline to week 4 before stabilising. HOMA-B increases were greater with all orforglipron doses than with dulaglutide. Additional β-cell function biomarkers, such as fasting proinsulin and the proinsulin/insulin ratio, also improved with orforglipron doses of 12 mg and higher compared with baseline and to a greater extent than seen with dulaglutide. HOMA-IR values decreased up to 16% (C-peptide) and 23% (insulin) with orforglipron by week 26. Reductions in HOMA-IR (insulin) were significant versus baseline only for the highest dose. IGFBP-2 and adiponectin, corollary biomarkers of insulin sensitivity, were generally improved with orforglipron.

CONCLUSIONS:

Increased HOMA-B and improved metabolic biomarkers suggest that treatment with the orally administered non-peptide GLP-1 receptor agonist orforglipron enhanced pancreatic β-cell function and insulin sensitivity in patients with T2D.

2025-08-14·BMJ

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.

Review

作者: Zhu, Zhiming ; White, Heath ; Jin, Yinghui ; Li, Qiang ; Li, Sheyu ; Macdonald, Helen ; White, Barbara ; Agarwal, Arnav ; Gao, Yiyuan ; Gan, Yu ; McDonald, Steve ; An, Jing ; Rydén, Lars ; Mao, Yunhe ; Yuan, Chi ; Sun, Feng ; Wang, Yanyan ; Vandvik, Per Olav ; Nong, Kailei ; Standl, Eberhard ; Brosius, Frank C ; Quigley, Matthew ; Zou, Xinyu ; Schnell, Oliver ; Zhai, Chunjuan ; Liu, Changhai ; Jeppesen, Britta Tendal ; Marx, Nikolaus ; Millard, Tanya ; Fan, Qinlin ; Pan, Xiaohui ; Agoritsas, Thomas ; Turner, Tari ; Guyatt, Gordon H ; Tian, Xin ; Shi, Qingyang

OBJECTIVE:

To provide up-to-date evidence on key benefits, harms, and uncertainties regarding medications for adults with type 2 diabetes.

DESIGN:

Living systematic review and network meta-analysis (NMA), using frequentist random effects and GRADE (grading of recommendations, assessment, development and evaluation) approaches. Updates are planned at least two times a year.

DATA SOURCES:

Medline and Embase, searched up to 31 July 2024 for the current iteration.

STUDY SELECTION:

Randomised controlled trials of at least 24 weeks comparing one or more medications with standard treatment, placebo, or each other.

RESULTS:

The systematic review and NMA includes 493 168 participants from 869 trials (adding 53 trials since October 2022) reporting data for 13 drug classes (63 drugs) and 26 outcomes of interest. Regarding benefits, moderate to high certainty evidence confirms the well established cardiovascular and kidney benefits of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and finerenone (the last for patients with established chronic kidney disease). The most effective drugs in reducing body weight were tirzepatide (mean difference (MD) -8.63 kg (95% confidence interval -9.34 to -7.93); moderate certainty) and orforglipron (MD -7.87 kg (-10.24 to -5.50); low certainty), followed by eight other GLP-1RAs (high to moderate certainty). Absolute benefits of medications vary substantially depending on the baseline risk of cardiovascular and kidney outcomes; risk-stratified absolute effects of medications are summarised using an interactive multiple comparisons tool (https://matchit.magicevidence.org/250709dist-diabetes/#!/). Regarding medication-specific harms, SGLT-2 inhibitors increase genital infections (odds ratio (OR) 3.29 (95% CI 2.88 to 3.77); high certainty) and ketoacidosis due to diabetes (OR 2.08 (1.45 to 2.99); high certainty), and probably increase amputations (OR 1.27 (1.01 to 1.61); moderate certainty); tirzepatide and GLP-1RAs probably increase severe gastrointestinal events (most increased risk with tirzepatide (OR 4.21 (1.87 to 9.49); moderate certainty)); finerenone increases severe hyperkalaemia (OR 5.92 (3.02 to 11.62); high certainty); and thiazolidinediones increase major osteoporotic fractures and probably increase hospitalisation for heart failure. Sulfonylureas, insulin, and dipeptidyl peptidase-4 inhibitors probably increase the risk of severe hypoglycaemia. There is low to very low certainty evidence for effects on other diabetes-related complications, including neuropathy and visual impairment. Despite interest in the issue, there is uncertainty about whether GLP-1RAs may reduce dementia (OR 0.92 (0.83 to 1.02); low certainty).

CONCLUSIONS:

This living systematic review provides a comprehensive summary of the cardiovascular, kidney, and weight loss benefits, as well as medication-specific harms of medications for adults with type 2 diabetes, including effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide.

SYSTEMATIC REVIEW REGISTRATION:

PROSPERO number: CRD42022325948. A more detailed protocol is available at https://data.aliveevidence.org/records/q02rv-km486.

READERS' NOTES:

This article is the first version of a living systematic review. It is linked to a living BMJ Rapid Recommendation and other living clinical practice guidelines, presenting risk stratified recommendations for patients with type 2 diabetes at lower, moderate, and higher risk of cardiovascular and kidney complications. The latest evidence will be made available via the BMJ Rapid Recommendation and via an interactive GRADE evidence summary (MATCH-IT: https://matchit.magicevidence.org/250709dist-diabetes/#!/). Major updates will be published in The BMJ.

471

项与奥格列龙相关的新闻（医药）

2025-09-27

·汇聚南药

8700万投入失败！

近期，糖尿病研发领域传来两个消息，一个好消息，一个坏消息。坏消息是，亚宝药业研发，历时7年，全球首创的SGLT1抑制剂SY-009胶囊宣告失败。好消息则是，中国生物制药自主研发的口服小分子GLP-1抑制剂TQF3250胶囊临床试验申请（IND）获受理。 9月23日，亚宝药业发布公告，终止一款糖尿病药物的研发，SY-009是一种钠-葡萄糖协同转运蛋白1（SGLT1）抑制剂。 SY-009是亚宝与礼来共同研发的项目，研发历时7年，早在2018年7月就获得临床批件，2019年4月至2024年3月期间完成了3项Ⅰ期临床研究和1项Ⅱ期临床研究，2024年9月SY-009获得新增适应症临床批件，批准了SY-009针对功能性便秘开展Ⅱ期临床试验的申请。终止原因据披露是因Ⅱ期临床研究结果疗效终点未达到，补充增加Ⅱ期临床剂量探索试验再开展Ⅲ期临床试验所需时间较长，后续研发投入巨大且存在较大不确定性。公告显示亚宝药业针对SY-009研发投入共计8786.98万元，其中费用化金额3207.65万元，资本化金额 5579.33万元。项目终止也就意味着这8700万付诸东流，并将直接影响亚宝药业2025年度利润总额减少超 5500 万元。这不是亚宝第一次失败，SGLT1单靶点抑制剂全球暂无产品上市，针对这个靶点，亚宝做了多次尝试。除了上述SY-009之外，亚宝还曾与礼来共同研发过另一款SY-008胶囊，早在2016年12月获批临床，后完成了Ia和Ib期临床研究。同样以失败告终，2024年下半年，亚宝宣布终止该项目后续研究，原因是结合糖尿病新型药物的研发上市情况和同靶点药物的研究进展，亚宝认为继续开发的风险较高，彼时亚宝就该项目已累计投入研发费用2950.65万元。针对SGLT1抑制剂，亚宝累计已投入过亿，均失败。 SGLT抑制剂有两个细分靶点：一个就是上述提到的SGLT1，除了亚宝之外，布局的厂商其实很少。更为出名的是SGLT2，知名大药众多，包括大名鼎鼎的恩格列净、达格列净等。 2023年，FDA批准了首个SGLT1和SGLT2双靶点抑制剂索格列净，但未在国内上市。亚宝药业SGLT1抑制剂，也是想拥有一款像达格列净一样的明星药物。虽然失败了，但勇气可嘉。另一边，9月19日，中国生物制药子公司正大天晴的一款口服GLP-1类药物TQF3250胶囊临床试验申请获受理，拟用于治疗2型糖尿病。 TQF3250是一款口服小分子偏向型GLP-1RA，能够通过选择性激活cAMP偏向的GLP-1R信号通路，高效促进胰岛素分泌。目前GLP-1抑制剂研发主流是多肽类药物，全球仅有一款口服GLP-1RA获批上市，即诺和诺德的司美格鲁肽片（Rybelsus），同样是多肽类。而礼来的Orforglipron，则是进度最快的口服小分子GLP-1药物，每一步临床数据结果都备受关注。正大天晴的这款TQF3250胶囊明显是紧跟礼来的Orforglipron进行的研发。 TQF3250胶囊临床前研究显示，在小鼠模型中，TQF3250在低至1mg/kg的剂量下显著改善糖耐量，其活性与同类药物礼来的Orforglipron相当，展现出高效降糖作用。正大天晴在降糖药管线布局了多款产品，2024年6月，正大天晴的利拉鲁肽注射液获批上市，2023年8月，司美格鲁肽注射液获批临床，2025年1月，复方制剂德古胰岛素利拉鲁肽注射液获批临床。此次正大天晴跳过了司美格鲁肽口服制剂研发，直接布局了口服小分子。希望能成功弯道超车。参考：药圈观察局、每日经济新闻喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~ 免责声明 “汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：药通社往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

临床2期临床申请临床1期临床3期临床终止

2025-09-26

·药研网

礼来终止Bimagrumab联用试验，对来凯医药ActRII管线影响几何？

2025年9月25日，礼来公司决定终止其一项评估在研抗体bimagrumab与Zepbound联用治疗肥胖症的IIb期临床试验。根据联邦临床试验数据库信息，此次终止纯粹出于“战略性商业原因”。截至发稿时，礼来未对BioSpace的置评请求作出回应。这一决定令业界感到意外，因为就在三个月前的美国糖尿病协会科学会议上，该联合疗法刚刚公布了令人鼓舞的二期临床试验数据。今年6月ADA大会上公布的数据显示，bimagrumab与司美格鲁肽联用可实现22.1%的总减重效果，其中92.8%来自脂肪减少，表现出更高的脂肪占比减重与更优的身体成分改善。作为对照，单用bimagrumab也能实现10.8%的总减重，且几乎全部来自脂肪减少。 Bimagrumab是一种全人源单克隆抗体，通过阻断II型激活素受体，从而抑制肌肉生长抑制素的活动。这一机制不仅能够减少脂肪堆积，还可能促进肌肉生长。这些数据原本为二期b试验提供了有力支持，脂肪减少比例高达92.8% 的表现，尤其令人对联合疗法的潜力充满期待。 01 战略考量优先尽管早期临床数据积极，礼来仍然做出了终止试验的商业决策。医药行业分析师指出，“战略性商业原因” 可能涉及多方面考量。礼来正将研发与商业资源聚焦于更具规模化潜力的单药路径：· 替尔泊肽注射剂（已拓展至阻塞性睡眠呼吸暂停适应症）；· 口服orforglipron（三项Ⅲ期试验连续成功，公司正配套建设超级产能）；· 三重激动剂retatrutide（已进入Ⅲ期临床）。相比之下，“GLP-1+抗体”联合疗法在成本控制、患者可及性及医保准入方面的商业化路径尚不明确，其投资回报周期也显著长于单药策略。目前其减重药物Zepbound已在市场上取得领先地位，联合疗法可能会影响现有产品的市场地位和生命周期管理。而联合疗法的开发可能面临复杂的商业决策：是推出联合疗法还是依次推出单药治疗？礼来可能评估认为，单独推进Zepbound及其更高剂量版本的市场拓展，比开发联合疗法更具商业价值。Zepbound作为目前效果最好的减重药物之一，市场接受度正在快速提升。这一资源倾斜决策，正契合其对外宣称的“战略性商业原因”。监管路径也是重要考量因素。联合疗法通常需要更复杂的审批流程，可能延迟产品上市时间。相比之下，优化现有药物剂量或开发新适应症可能是更快捷的市场扩张方式。另一方面，礼来可能也在规划后续产品线，避免同类产品之间的内部竞争。将bimagrumab用于其他适应症，如肌肉减少症，可能创造更大的市场价值。 02 对来凯医药的影响礼来终止bimagrumab联合试验对来凯医药（ActRII靶点管线）的影响呈现短期情绪承压与长期价值分化的特点。市场可能因礼来的决策对来凯ActRII同靶点产品产生担忧。但需明确，礼来此次终止标注为商业策略调整，并非针对靶点机制或安全性的否定，其在该方向的探索与合作仍在持续。来凯的差异化在于聚焦“肌少性肥胖”及身体功能改善，而非单纯减重。· LAE102（ActRIIA单抗）已在2025年ADA公布I期数据，显示安全性与潜在疗效信号；· LAE103（ActRIIB选择性抗体）已获FDA临床试验许可；· LAE123（A/IIB双靶）处于临床前阶段。其路径更注重肌肉保存与功能提升，有望与主流GLP-1药物形成协同或差异化补充。值得注意的是，礼来与来凯的合作关系并未受到影响。自2024年11月起，礼来在美国承担LAE102一项I期试验费用，来凯保留全球权益。这一安排表明礼来仍认可ActRII方向的科学价值，只是内部优先级有所调整。此外，再生元、Scholar Rock等企业在“保肌+GLP-1”领域已取得阳性人体数据，虽抬高了后续临床试验的比对标准，但也为赛道进行了市场与监管教育，降低机制认同门槛。整体而言，来凯的中长期价值仍取决于其临床路径设计的精准性与数据质量，仍有机会在细分人群中建立差异化优势。礼来的战略调整虽带来短期波动，但并未改变ActRII靶点在肌肉-代谢领域的长期潜力。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载/商务/投稿 | 联系微信15618157102（sum_Gmi）商务合作稿件征集点击了解详情往期回顾 BD十年回顾：跨国药企的交易趋势与逻辑洞察行业观察：裁员浪潮为什么还在席卷生物医药？

临床2期临床3期临床成功临床失败临床结果

2025-09-26

·BioPharmaDive

Crinetics drug to challenge pharma ‘Goliaths’; FDA, ARPA move to speed gene therapies

Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Today, a brief rundown of news involving Crinetics and the Food and Drug Administration, as well as updates from Eli Lilly, Biogen and Gossamer Bio that you may have missed.Crinetics on Thursday won clearance from U.S. regulators to begin selling a new drug for the rare hormonal disorder acromegaly. Called Palsonify and, previously paltusotine, the drug is the first once-daily oral therapy for the condition and cleared for adults who aren't eligible for corrective surgery or haven't adequately responded to it. Palsonify is “poised to challenge the Goliaths of pharma,“ among them Novartis and Pfizer, with a “broad label and an attractive [annual] $290,000 list price,“ wrote Leerink Partners' Joseph Schwartz, who is predicting $375 million in peak yearly sales in the U.S. and Europe. Ben FidlerThe federal government this week announced multiple new initiatives designed to foster gene therapy research. The Food and Drug Administration on Wednesday published draft guidance outlining accelerated approval pathways, post-approval requirements and new clinical trial designs. And on Thursday, the Advanced Research Projects Agency debuted two programs aiming to speed development and assist with manufacturing, so the complex medicines are less costly to produce. Ben FidlerBristol Myers Squibb will begin selling its psoriasis drug Sotyktu online at a discounted price, the company said Thursday. Starting in January, Bristol Myers will offer Sotyktu at a cost more than 80% lower than its current list price for people who are uninsured, underinsured or pay for the medicine out of pocket. The initiative is part of a growing trend among pharmaceutical companies to provide products directly to consumers while bypassing traditional drug distribution channels. Bristol Myers started offering its heart drug Eliquis online at a reduced price this month. Ben FidlerEli Lilly announced the location of the second of the four new U.S. manufacturing plants it intends to build, a factory in Houston that will make the active ingredients for several small molecule drugs, including its experimental obesity medicine orforglipron. Lilly will pour $6.5 billion into the factory, which it says will employ 4,000 peopleduring constructionand 615 at the plant once it is operational in five years. Earlier this month, the company said it will locate another plant near Richmond, Virginia,as part of a promise to spend $50 billion on domestic manufacturing. Details regarding the two other factories will be announced this year. Jonathan GardnerThe FDA rejected a high-dose version of Biogens spinal muscular atrophy drug Spinraza. Study results last year showed that the newer form of Biogens drug appeared to slow neurodegeneration faster than the marketed treatment and, according to Biogen, the agency didnt cite any deficiencies with its clinical data. Instead, the FDA requested an update to certain technical information in the portion of its application dealing with manufacturing. Biogen intends to respond and update its application promptly, but its unclear whether the resubmission will be a Class 1 or Class 2 filing, each of which have different review timelines, wrote William Blair analyst Myles Minter. Ben FidlerGossamer Bio secured an option to acquire privately held pulmonary arterial hypertension drug developer Respira Therapeutics, the companies said Thursday. The deal provides Respira with funding to develop its lead candidate, an inhaled drug called RT234, for up to two years as the companies advance development. Respira completed a Phase 2b studyearlier this year.Gossamer issued 2.5 million shares of common stock upon signing the deal, and would add another 1.5 million if it exercises the acquisition option. Last year, Gossamer sold rights to its own PAH drug, seralutinib,to Italy-based Chiesi Farmaceutici. Gwendolyn WuAn experimental drug Harmony Bioscienceshas been developing for Fragile X syndrome failed a late-stage trial. In a Wednesday announcement, the company said its drug, ZYN002, failed to meet its main goal of improving social avoidance because of a higher than expected placebo response rate. Harmony acquired ZYN002, a topical, synthetic cannabidiol, in a 2023 buyout of Zynerba Pharmaceuticals. The compound previously failed studies in epilepsy and osteoarthritis-related knee pain. Gwendolyn Wu '

并购临床2期上市批准

100 项与奥格列龙相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床3期	美国	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	中国	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	日本	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	加拿大	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	德国	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	印度	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	墨西哥	Eli Lilly & Co.	2025-09-01
膝关节炎	临床3期	西班牙	Eli Lilly & Co.	2025-09-01
高血压	临床3期	美国	Eli Lilly & Co.	2025-04-30
高血压	临床3期	中国	Eli Lilly & Co.	2025-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05872620 (ATTAIN-2, Company_Website) 人工标引	临床3期	2型糖尿病 \| 超重 \| 肥胖	-	Orforglipron 6 mg	窪壓積壓餘蓋廠繭簾獵(繭糧廠膚繭鑰願觸鹽觸) = 鹽繭遞憲範鏇鏇憲壓膚艱鹹餘膚鹽餘網製觸鑰 (壓糧範鹽範構選製觸築 ) 更多	积极	2025-08-26
				Orforglipron 12 mg	窪壓積壓餘蓋廠繭簾獵(繭糧廠膚繭鑰願觸鹽觸) = 網蓋觸鬱製鏇醖網鏇遞艱鹹餘膚鹽餘網製觸鑰 (壓糧範鹽範構選製觸築 ) 更多
NCT05869903 (ATTAIN-1, NEWS) 人工标引	临床3期	超重 \| 肥胖	-	orforglipron	繭糧鬱願獵鬱鹹範窪淵(壓選築壓鬱齋鏇糧憲膚) = orforglipron的三个剂量组与安慰剂组相比均达到了主要终点獵鹹築積夢製積範蓋廠 (淵簾齋遞糧範憲鏇繭獵 ) 达到更多	积极	2025-08-07
				安慰剂
NCT05971940 (ACHIEVE-1, Pubmed \| N Engl J Med) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mg	蓋膚鬱構築醖範鏇範願(壓糧網繭觸廠獵願醖築) = 廠鏇遞顧膚簾顧觸簾淵選願鬱醖夢鹹糧築觸獵 (餘醖願襯築鑰淵憲築繭 ) 更多	积极	2025-06-21
				Orforglipron 12 mg	蓋膚鬱構築醖範鏇範願(壓糧網繭觸廠獵願醖築) = 範顧鏇齋積衊膚簾艱選選願鬱醖夢鹹糧築觸獵 (餘醖願襯築鑰淵憲築繭 ) 更多
NCT05971940 (ACHIEVE-1, Biospace \| NEWS) 人工标引	临床3期	2型糖尿病	559	Orforglipron 3 mgOrforglipron 3 mg	鬱鹽鑰壓餘齋積獵艱獵(築選鏇憲鏇繭襯鑰膚構) = 襯憲簾築築齋簾醖壓觸願遞顧鑰鑰願廠繭築選 (顧糧範淵餘壓鏇簾衊齋 ) 达到更多	积极	2025-04-17
				OrforglipronOrforglipron 12 mg	鬱鹽鑰壓餘齋積獵艱獵(築選鏇憲鏇繭襯鑰膚構) = 淵艱鹽獵淵構夢繭製觸願遞顧鑰鑰願廠繭築選 (顧糧範淵餘壓鏇簾衊齋 ) 达到更多
NCT05051579 (EASD2023)	临床2期	超重 \| 肥胖	272	Orforglipron (OFG) 12 mg	繭襯鑰鬱壓鹽壓簾鏇遞(顧夢艱窪範膚積膚襯構) = 繭齋糧鑰鹹願鑰鏇製衊齋淵鹽觸餘遞積醖積餘 (鏇壓鏇蓋襯醖繭壓獵淵 ) 更多	积极	2023-10-03
				Orforglipron (OFG) 24 mg	繭襯鑰鬱壓鹽壓簾鏇遞(顧夢艱窪範膚積膚襯構) = 鬱繭選獵醖選膚繭艱衊齋淵鹽觸餘遞積醖積餘 (鏇壓鏇蓋襯醖繭壓獵淵 ) 更多
NCT05051579 (GZGI, CTgov)	临床2期	肥胖	272	LY3502970 (24 mg LY3502970)	衊範襯窪淵蓋鏇築衊餘(夢夢壓憲遞淵獵蓋觸積) = 選蓋願遞鹹鑰鏇鬱憲顧鬱鏇糧餘簾醖簾繭鏇鬱 (蓋衊淵製製衊壓衊構鬱, 0.82) 更多	-	2023-09-13
				Placebo (Placebo)	衊範襯窪淵蓋鏇築衊餘(夢夢壓憲遞淵獵蓋觸積) = 製觸鏇鑰壓齋顧獵壓夢鬱鏇糧餘簾醖簾繭鏇鬱 (蓋衊淵製製衊壓衊構鬱, 0.81) 更多
NCT05048719 (ADA 12023 \| ADA 22023) 人工标引	临床2期	2型糖尿病	383	Orforglipron 3 mg	遞艱鏇鬱糧選膚壓餘範(築廠餘顧繭蓋鹹壓顧網) = 襯積齋餘願壓願鑰壓蓋顧鬱夢衊壓簾獵襯衊夢 (選襯顧齋範遞齋窪廠醖 ) 更多	积极	2023-06-25
				Orforglipron 12 mg	遞艱鏇鬱糧選膚壓餘範(築廠餘顧繭蓋鹹壓顧網) = 蓋廠構鑰艱範艱鹹鹹鹹顧鬱夢衊壓簾獵襯衊夢 (選襯顧齋範遞齋窪廠醖 ) 更多
NCT05051579 (ADA 12023 \| ADA 22023) 人工标引	临床2期	超重 \| 肥胖	272	Orforglipron 12 mg	窪膚願繭範窪鬱築壓糧(蓋壓醖襯觸膚鹽醖構積) = 鏇壓觸餘衊廠蓋獵構範鹽壓糧憲製鑰簾膚網廠 (鹹餘築鹽膚膚選簾衊觸 ) 更多	积极	2023-06-23
				Orforglipron 24 mg	窪膚願繭範窪鬱築壓糧(蓋壓醖襯觸膚鹽醖構積) = 範願襯遞憲簾簾糧餘艱鹽壓糧憲製鑰簾膚網廠 (鹹餘築鹽膚膚選簾衊觸 ) 更多
NCT05048719 (Literature \| Pubmed \| Lancet) 人工标引	临床2期	2型糖尿病	303	orforglipron	廠獵餘鬱簾築遞築壓鑰(製觸獵鬱構糧築製襯選) = 壓繭願積齋鹽鑰範範艱範簾蓋鹽構糧廠觸艱窪 (餘淵衊鹹壓範壓繭鏇蓋 ) 更多	积极	2023-06-23
				Dulaglutide	廠獵餘鬱簾築遞築壓鑰(製觸獵鬱構糧築製襯選) = 繭簾選襯餘夢遞艱鏇衊範簾蓋鹽構糧廠觸艱窪 (餘淵衊鹹壓範壓繭鏇蓋 ) 更多
NCT05051579 (GZGI, Pubmed)	临床2期	肥胖	272	Orforglipron 12 mg	鹹憲醖觸觸願艱窪願醖(願膚蓋鹹繭顧襯鑰衊範) = 夢膚艱蓋淵範膚網鹹積鹹積顧鑰顧觸蓋構鬱觸 (餘鬱獵鹽選遞醖壓獵鬱 )	-	2023-06-23
				Orforglipron 24 mg	鹹憲醖觸觸願艱窪願醖(願膚蓋鹹繭顧襯鑰衊範) = 醖蓋膚觸網築築膚鹹膚鹹積顧鑰顧觸蓋構鬱觸 (餘鬱獵鹽選遞醖壓獵鬱 )